Dendrimers toward translational nanotherapeutics: concise key step analysis

• Autor(a) principal: Mignani, Serge
• Data de Publicação: 2020
• Outros Autores: Shi, Xiangyang, Rodrigues, João, Roy, René, Muñoz-Fernández, Ángeles, Ceña, Valentin, Majoral, Jean Pierre
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.13/4092
• topic: Nanomedicine; Dendrimers; Translational nanotherapeutics; Nanotherapeutics; .; Faculdade de Ciências Exatas e da Engenharia; Centro de Química da Madeira

The goal of nanomedicine is to address specific clinical problems optimally, to fight human diseases, and to find clinical relevance to change clinical practice. Nanomedicine is poised to revolutionize medicine via the development of more precise diagnostic and therapeutic tools. The field of nanomedicine encompasses numerous features and therapeutic disciplines. A plethora of nanomolecular structures have been engineered and developed for therapeutic applications based on their multitasking abilities and the wide functionalization of their core scaffolds and surface groups. Within nanoparticles used for nanomedicine, dendrimers as well polymers have demonstrated strong potential as nanocarriers, therapeutic agents, and imaging contrast agents. In this review, we present and discuss the different criteria and parameters to be addressed to prepare and develop druggable nanoparticles in general and dendrimers in particular. We also describe the major requirements, included in the preclinical and clinical roadmap, for NPs/dendrimers for the preclinical stage to commercialization. Ultimately, we raise the clinical translation of new nanomedicine issues.